scholarly journals Use of pyrenemethyl laurate for fluorescence-based determination of lipase activity in intact living lymphoblastoid cells and for the diagnosis of acid lipase deficiency

1993 ◽  
Vol 294 (3) ◽  
pp. 885-891 ◽  
Author(s):  
A Nègre-Salvayre ◽  
A Dagan ◽  
S Gatt ◽  
R Salvayre

Pyrenemethyl laurate (PMLes), a fluorogenic substrate for determining in vitro lipase activity [Nègre, Salvayre, Dagan and Gatt (1989) Biochim. Biophys. Acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with Wolman disease, which is characterized by a deficiency of lysosomal acid lipase. The intracellular degradation of PMLes was dependent on the mode of administration of the substrate into the cells, and occurred by two separate pathways involving lysosomal and extra-lysosomal hydrolases. PMLes incorporated into LDL was taken up by normal lymphoblastoid cells through the apolipoprotein-B/E-receptor-mediated pathway and degraded in the lysosomal compartment, as suggested by the degradation block in Wolman cells. In contrast, when PMLes dissolved in 2% dimethyl sulphoxide was added directly to the culture medium, its hydrolysis was similar in lymphoblastoid cells from controls and from patients affected with Wolman disease, neutral lipid storage disease or familial hypercholesterolaemia. This suggested that the administered PMLes was degraded by a non-lysosomal enzyme which is not deficient in Wolman cells. This enzyme also differs from the neutral lipase system which is deficient in lymphoblastoid cells from patients with neutral lipid storage disease. When pyrenemethanol was administered directly to the cell culture, it was only poorly acylated and was rapidly released into the culture medium. These results and the fluorescence properties of PMLes (‘monomeric’ emission in a hydrophobic environment and ‘excimeric’ emission in a hydrophilic environment) and pyrenemethanol (‘monomeric’ emission in a hydrophilic environment) allowed us to design a ‘direct reading’ procedure by monitoring (without any lipid extraction) the fluorescence of intact living cells and that of the culture medium during pulse-chase experiments. This method allowed the direct evaluation of the time course of in situ degradation of PMLes. In pulse-chase experiments with LDL-PMLes, the fluorescence of normal cells decreased relatively rapidly with time whereas the fluorescence of the culture medium increased concomitantly. With Wolman cells, the cellular fluorescence decreased only very slightly, whereas that of the culture medium remained at the basal level; this demonstrates the catabolic block in intact living cells from patients with Wolman disease. In vitro degradation of PMLes indicated the existence of two PMLes-degrading enzymes in lymphoblastoid cell homogenates: one is the acid lipase which is involved in PMLes degradation in the lysosomal compartment (and is deficient in Wolman cells), while the second is a cytoplasmic enzyme (not deficient in Wolman cells).

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Rajarajan Kuppusamy ◽  
Becca Feistritzer ◽  
Marc Engels ◽  
Anthony Sturzu ◽  
Karolina Plonowska ◽  
...  

Induced pluripotent stem cells (iPSCs) hold great promise as in vitro disease models for pathway discovery and therapeutic drug screening. Here, we generated an in vitro model of neutral lipid storage disease, myopathy subtype (NLSD-M), a condition characterized by a marked elevation of lipid accumulation in cardiac and skeletal muscle due to the loss of functional adipose triglyceride lipase (ATGL), by reprogramming patient fibroblasts into iPSCs. These hiPSCs were confirmed of carrying mutations in exon 5and exon 7 of the ATGL gene and were shown to recapitulate the disease phenotype by the presence of Oil Red O positive lipid granules in cardiomyocytes. To corroborate this finding, expression of metabolic genes such as Peroxisome proliferator-activated receptors (PPAR-a and PPAR-g) were significantly decreased in diseased cardiomyocytes compared to control. Furthermore, the down-regulation of PPAR-gamma coactivators (PGC-1a and PGC-1b) and PPAR target genes expression were associated with increased lipid accumulation in vitro. Utilizing the previously identified compounds that induces glycolysis and suppresses oxidative respiration, we found that the accumulation of intracellular lipids in cardiomyocytes was reduced in treated cells when compared with un-treated cells (0.041 ± 0.02 vs 0.186 ± 0.05). Strikingly, such a treatment effect was not observed when Wild Type iPSC derived cardiomyocytes was studied instead, suggesting a disease-specific effect of the identified drugs. Our results represent one of the first successful human induced Pluripotent Stem Cell validation of high throughput drug screening hits from murine iPSC lines. Given the increased prevalence of NLSD-Min the Japanese population, our findings raise the prospect that a treatment for this devastating disease using drug hits from in vitro iPSC screening may be feasible in the near future.


1994 ◽  
Vol 297 (3) ◽  
pp. 467-473 ◽  
Author(s):  
N Hilaire ◽  
A Nègre-Salvayre ◽  
R Salvayre

High-density lipoprotein (HDL)-[3H]triolein (i.e. [3H]triolein incorporated into reconstituted HDL) was taken up by cultured fibroblasts through an apparently saturable process, competitively inhibited by non-labelled HDL and independent of the LDL receptor. Using 125I-HDL and HDL-[3H]triolein, binding experiments (at 0 degrees C) followed by a short-time ‘chase’ at 37 degrees C showed that 125I radioactivity was rapidly released in the culture medium (as trichloroacetic acid-precipitable material), whereas 3H radioactivity remained associated with the cell. The cell-associated HDL-[3H]triolein was rapidly degraded in normal fibroblasts, and the liberated [3H]oleic acid was incorporated into newly biosynthesized phospholipids. In Wolman-disease fibroblasts HDL-[3H]triolein was degraded at a normal rate, and thus independently of the lysosomal compartment. In contrast, the degradation of HDL-[3H]triolein was blocked in fibroblasts from Neutral Lipid Storage Disease (NLSD), similarly to that of endogenously biosynthesized triacylglycerols [Radom, Salvayre, Nègre, Maret and Douste-Blazy (1987) Eur. J. Biochem. 164, 703-708]. Trypsin-treated HDL-[3H]triolein was also taken up by cells and degraded quite similarly to HDL-[3H]triolein. In conclusion, all these data taken together suggest that HDL-[3H]triolein is: (i) associated with the cell through a process independent of intact apolipoprotein (apo) As, thus probably independent of an apoA-receptor-mediated uptake; (ii) internalized by cells, whereas 125I-apoAs are released in the culture medium; (iii) directed to the same non-lysosomal catabolic pool (blocked in NLSD) as for endogenously biosynthesized triacylglycerols.


2018 ◽  
Vol 28 (7) ◽  
pp. 606-609 ◽  
Author(s):  
Caitlin S. Latimer ◽  
Jennifer Schleit ◽  
Adam Reynolds ◽  
Desiree A. Marshall ◽  
Benjamin Podemski ◽  
...  

2020 ◽  
Vol 83 (3) ◽  
pp. 317-322
Author(s):  
Makoto Samukawa ◽  
Naoko Nakamura ◽  
Makito Hirano ◽  
Miyuki Morikawa ◽  
Hanami Sakata ◽  
...  

Mutations in the PNPLA2 gene cause neutral lipid storage disease with myopathy (NLSDM) or triglyceride deposit cardiomyovasculopathy. We report a detailed case study of a 53-year-old man with NLSDM. The PNPLA2 gene was analyzed according to the reported method. We summarized the clinical, laboratory, and genetic information of 56 patients, including our patient and 55 other reported patients with homozygous or compound heterozygous mutations in the PNPLA2 gene. We found a novel homozygous mutation (c.194delC) in the PNPLA2 gene that resulted in frameshift. The patient suffered from normal-tension glaucoma and pulmonary cysts, symptoms that are relatively common in the elderly but were not previously reported for this disease. Our summary confirmed that Jordan’s anomaly, polymorphonuclear leukocytes with lipid accumulation, was the most consistent finding of this disease. Because this disease is potentially treatable, our results may help rapid and correct diagnosis.


1994 ◽  
Vol 153 (3) ◽  
pp. 210-211 ◽  
Author(s):  
A. Dursun ◽  
A. Kubar ◽  
A. Gokoz ◽  
F. Duru ◽  
A. Gürgey

Sign in / Sign up

Export Citation Format

Share Document